BARONE, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 17.238
EU - Europa 6.264
AS - Asia 5.343
SA - Sud America 917
OC - Oceania 200
AF - Africa 46
Continente sconosciuto - Info sul continente non disponibili 16
Totale 30.024
Nazione #
US - Stati Uniti d'America 17.032
SG - Singapore 2.010
CN - Cina 1.661
UA - Ucraina 1.409
IT - Italia 1.386
RU - Federazione Russa 908
BR - Brasile 843
DE - Germania 735
IE - Irlanda 632
VN - Vietnam 469
KR - Corea 412
TR - Turchia 386
SE - Svezia 329
FI - Finlandia 308
GB - Regno Unito 169
HK - Hong Kong 160
EE - Estonia 146
CA - Canada 144
NZ - Nuova Zelanda 102
AU - Australia 98
IN - India 86
NL - Olanda 47
AT - Austria 42
FR - Francia 39
MX - Messico 37
CZ - Repubblica Ceca 28
AR - Argentina 24
JP - Giappone 22
BD - Bangladesh 21
IQ - Iraq 20
PL - Polonia 18
EU - Europa 16
UZ - Uzbekistan 15
EC - Ecuador 13
ES - Italia 13
PK - Pakistan 12
IL - Israele 11
MA - Marocco 11
ZA - Sudafrica 11
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
BE - Belgio 8
CO - Colombia 7
ID - Indonesia 7
KE - Kenya 7
CL - Cile 6
NP - Nepal 6
PY - Paraguay 6
DK - Danimarca 5
DO - Repubblica Dominicana 5
EG - Egitto 5
GR - Grecia 5
JM - Giamaica 5
LT - Lituania 5
SA - Arabia Saudita 5
CH - Svizzera 4
CR - Costa Rica 4
IR - Iran 4
LU - Lussemburgo 4
PH - Filippine 4
RO - Romania 4
TN - Tunisia 4
TW - Taiwan 4
AZ - Azerbaigian 3
BO - Bolivia 3
JO - Giordania 3
PA - Panama 3
PE - Perù 3
UY - Uruguay 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
DZ - Algeria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MK - Macedonia 2
NI - Nicaragua 2
NO - Norvegia 2
RS - Serbia 2
SV - El Salvador 2
AO - Angola 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MN - Mongolia 1
Totale 30.016
Città #
Ann Arbor 4.156
Wilmington 2.250
Jacksonville 1.728
Princeton 1.634
Chandler 1.535
Houston 729
Singapore 726
Woodbridge 616
Dublin 593
Dong Ket 459
Ashburn 428
Nanjing 399
Andover 368
Izmir 364
Beijing 324
Moscow 312
Boardman 297
Pellezzano 264
Düsseldorf 216
Mestre 203
Hong Kong 154
Naples 147
Tallinn 146
Norwalk 143
Shenyang 134
Fairfield 131
Hebei 121
Salerno 120
Changsha 110
Nanchang 108
Dearborn 107
Munich 90
Los Angeles 87
Jiaxing 85
Redwood City 60
São Paulo 60
Rome 59
Dallas 56
The Dalles 56
Tianjin 56
San Diego 49
Nuremberg 47
Pune 46
Auckland 43
Sydney 42
Milan 35
West Jordan 35
New York 33
Turku 32
Belo Horizonte 31
Cambridge 31
Washington 31
San Francisco 30
Jinan 29
Seattle 29
Amsterdam 27
Columbus 27
Ottawa 27
Rio de Janeiro 25
Council Bluffs 21
Guangzhou 21
Montreal 21
Brasília 20
Fort Worth 20
Lappeenranta 20
Springfield 19
Stockholm 19
Casoria 18
Venezia 18
Shanghai 17
Melbourne 16
Brno 15
Brooklyn 15
Campinas 14
Curitiba 14
Lecce 14
Santa Clara 14
Vienna 14
Hangzhou 13
Tashkent 13
Bologna 12
Brisbane 12
Christchurch 12
Hamilton 12
Prineville 12
Tokyo 12
Atlanta 11
Chicago 11
Perth 11
Porto Alegre 11
Dormagen 10
Fuzhou 10
Kunming 10
London 10
Napoli 10
Phoenix 10
Pompei 10
Ribeirão Preto 10
Warsaw 10
Wuhan 10
Totale 20.852
Nome #
Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. 165
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. 161
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 156
Validation of the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS) 151
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. 143
Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS) 140
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. 136
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 132
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 128
Neuropsychological correlates of Pisa syndrome in patients with Parkinson's disease 127
Accuracy of clinical diagnostic criteria for Friedreich'sataxia. 125
The natural history of multiple system atrophy: A prospective European cohort study 121
MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. 119
The PRIAMO study: background, methods and recruitment. Apr;29(2):61-5. .PMID: 18483702 117
Are granular osmiophilic material deposits an epiphenomenon in CADASIL? 115
Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study 115
Normative data for the Montreal Cognitive Assessment in an Italian population sample 114
Increased bilirubin levels in de novo Parkinson's disease 113
Affective theory of mind in patients with Parkinson's disease: comment 113
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: A randomised, placebo-controlled trial 112
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 111
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 109
Long-term safety of rivastigmine in parkinson disease dementia: An open-label, randomized study 109
The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study 108
Regional gray matter atrophy in patients with Parkinson disease and freezing of gait 107
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. 106
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 104
Sindromi parkinsoniane 104
Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations 102
Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment 102
The alpha-synuclein gene in multiple system atrophy 101
Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. 100
An easy tool to improve accuracy in pre-diagnostic Parkinson's disease population 100
The accuracy of the arginine growth hormone test in parkinsonism. 99
D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine. 99
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 98
Diagnosis and management of Parkinson's disease dementia. Oct;62(10):1581-7. Review.PMID: 18822028 97
Gender and non motor fluctuations in Parkinson's disease: A prospective study 97
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 97
Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study 97
Malabsorption is uncommon in restless legs syndrome. 95
Aiming for study comparability in Parkinson's disease: Proposal for a modular set of biomarker assessments to be used in longitudinal studies 95
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 94
Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study 94
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 94
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 94
Apathy and related executive syndromes in dementia associated with Parkinson's disease and in Alzheimer's disease 93
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 93
Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. 92
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Aug 15;23(11):1532-40.PMID: 18581467 92
Prophylaxis of migraine attacks with a calcium-channel blocker: flunarizine versus methysergide 92
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 92
Pisa syndrome in Parkinson disease: An observational multicenter Italian study 92
A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients 92
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 92
Dopamine mediated responses in 6-OH-DA lesioned rats involve changes of the signal transduction. 91
Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. 91
Is the dexamethasone suppression test predictive of response to specific antidepressant treatment in major depression? 91
Bilirubin and Uric Acid: Two Different Anti-oxidants in Parkinson’s Disease 91
On the relationship between side of onset and cognition in Parkinson disease 90
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study 90
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 89
Nitric oxide-haemoglobin interaction: a new biochemical hypothesis for signal changes in fMRI. 89
Adherence to anti-Parkinson drug therapy in the ?REASON? sample of Italian patients with Parkinson?s disease: the linguistic validation of the Italian version of the ?Morisky Medical Adherence scale-8 items? 89
PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family 89
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease 89
A longitudinal study of cognitive dysfunction in patients affected by Parkinson’s disease with and without freezing of gait 89
Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates 88
The relevance of gender in Parkinson's disease: a review 88
Speech discrimination is impaired in parkinsonian patients: Expanding the audiologic findings of Parkinson's disease 88
Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease 88
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. 87
Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. 87
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Sep;132(Pt 9):2350-5. PMID: 19584099 87
Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors. 87
Short-latency afferent inhibition in patients with Parkinson’s disease and freezing of gait 87
Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards 87
Apathy in Parkinson's disease: Diagnosis, neuropsychological correlates, pathophysiology and treatment 87
Quitting smoking: An early non-motor feature of Parkinson's disease? 86
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. 86
Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors. 86
D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models andparkinsonian patients. 86
Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease 86
Pramipexole in patients with early Parkinson's disease (PROUD): A randomised delayed-start trial 86
Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease-Report of the JPND Working Group BioLoC-PD 86
Assessment of apathy minimising the effect of motor dysfunctions in Parkinson’s disease: a validation study of the dimensional apathy scale 86
Early MRI findings in acquired hepatocerebral degeneration. 85
Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale 85
Abnormal eating behaviors in progressive supranuclear palsy. 84
Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and (L)-dopa-undertreated Parkinson disease: a double-blind, randomized trial. 84
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 84
Plasma prolactin response to sodium valproate in epileptic patients 84
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 84
Bisphenol A glucuronidation in patients with Parkinson's disease 84
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations 84
Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations 84
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 84
Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Oct;16(10):1090-9. Review.PMID: 19723294 83
Dopamine D1 and D2 receptors mediate opposite functions in seizures induced by lithium-pilocarpine. 83
Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade. 83
Totale 9.948
Categoria #
all - tutte 124.512
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.512


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.645 24 248 270 10 363 136 344 19 305 22 341 563
2021/20222.615 14 4 14 25 23 16 40 112 405 368 356 1.238
2022/20234.002 472 174 97 355 656 927 20 382 628 18 187 86
2023/20242.059 159 310 110 162 100 197 86 131 71 138 175 420
2024/20256.305 260 60 145 369 216 669 731 686 911 692 741 825
2025/202657 57 0 0 0 0 0 0 0 0 0 0 0
Totale 31.092